Dual energy CT for monitoring targeted therapies in patients with advanced gastrointestinal stromal tumor: Initial results

Current Pharmaceutical Biotechnology

Volumn 12, Issue 4, 2011, Pages 547-557

  Schramm, N ^a   Schlemmer, M ^a   Englhart, E ^a   Hittinger, M ^a   Becker, C ^a   Reiser, M ^a   Berger, F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Dual energy CT; GIST; Targeted therapy; Therapy monitoring

Indexed keywords

IMATINIB; IODINE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DRUG SUBSTITUTION; DRUG UPTAKE; DRUG WITHDRAWAL; DUAL ENERGY COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MOLECULAR THERAPY; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DATA INTERPRETATION, STATISTICAL; DRUG MONITORING; FEASIBILITY STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IOHEXOL; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79953767969     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795164066     Document Type: Article

References (32)

1. Rosai, J. Gastrointestinal tract. Ackermanś Surgical Pathology, St Louis, MO, Mosby Year-Book 1996.
2. Joensuu, H.; Roberts, P. J.; Sarlomo-Rikala, M.; Andersson, L. C.; Tervahartiala, P.; Tuveson, D.; Silberman, S.; Capdeville, R.; Dimitrijevic, S.; Druker, B.; Demetri, G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med., 2001, 344, (14), 1052-1056.
3. Le Tourneau, C.; Raymond, E.; Faivre, S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Clin. Risk Manag., 2007, 3, (2), 341-348.
4. Montemurro, M.; Schoffski, P.; Reichardt, P.; Gelderblom, H.; Schutte, J.; Hartmann, J. T.; von Moos, R.; Seddon, B.; Joensuu, H.; Wendtner, C. M.; Weber, E.; Grunwald, V.; Roth, A.; Leyvraz, S. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur. J. Cancer, 2009, 45(13), 2293-2297.
5. Van den Abbeele, A. D.; Badawi, R. D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer, 2002, 38 (Suppl 5), S60-65.
6. Van den Abbeele, A.D. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist, 2008, 13 (Suppl 2), 8-13.
7. Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A. T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 2000, 92 (3), 205-216.
8. Eisenhauer, E. A.; Therasse, P.; Bogaerts, J.; Schwartz, L. H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
9. Choi, H.; Charnsangavej, C.; de Castro Faria, S.; Tamm, E. P.; Benjamin, R. S.; Johnson, M. M.; Macapinlac, H. A.; Podoloff, D. A. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR. Am. J. Roentgenol., 2004, 183(6), 1619-1628.
10. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov., 2007, 6 (9), 734-745.
11. Choi, H.; Charnsangavej, C.; Faria, S. C.; Macapinlac, H. A.; Burgess, M. A.; Patel, S. R.; Chen, L. L.; Podoloff, D. A.; Benjamin, R. S. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol., 2007, 25 (13), 1753-1759.
12. Jin, T.; Nakatani, H.; Taguchi, T.; Nakano, T.; Okabayashi, T.; Sugimoto, T.; Kobayashi, M.; Araki, K. STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1. World J. Gastroenterol., 2006, 12 (5), 703-708.
13. Miles, K. A. Cuenod, C.A. Eds, Multidetector Computed Tomography in Oncology. Informa Healthcare, UK, 2007.
14. Graser, A.; Johnson, T. R.; Chandarana, H.; Macari, M, Dual energy CT: preliminary observations and potential clinical applications in the abdomen. Eur. Radiol., 2009, 19(1), 13-23.
15. Kruger, R. A.; Riederer, S. J.; Mistretta, C. A. Relative properties of tomography, K-edge imaging, and K-edge tomography. Med. Phys., 1977, 4(3), 244-249.
16. Riederer, S. J.; Mistretta, C. A. Selective iodine imaging using Kedge energies in computerized x-ray tomography. Med. Phys., 1977, 4(6), 474-481.
17. Plaat, B. E.; Hollema, H.; Molenaar, W. M.; Torn Broers, G. H.; Pijpe, J.; Mastik, M. F.; Hoekstra, H. J.; van den Berg, E.; Scheper, R. J.; van der Graaf, W. T. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J. Clin. Oncol., 2000, (18), 3211-20.
18. Cassier, P.A.; Dufresne, A.; Arifi, S.; El Sayadi, H.; Labidi, I.; Ray-Coquard, I.; Ranchere, D. Sunyache, M.P.; Decouveleare A.V.; Alberti, L.; Blay, J.Y. Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert. Opin. Pharmacother., 2008, 9, 1211-1222.
19. Van den Abbeele, A. D. The Lessons of GIST-PET and PET/CT: A New Paradigm for Imaging. Oncologist, 2008, 13(suppl 2)), 8-13.
20. Antoch, G.; Kanja, J.; Bauer, S.; Kuehl, H.; Renzing-Koehler, K.; Schuette, J.; Bockisch, A.; Debatin, J. F.; Freudenberg, L. S. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J. Nucl. Med., 2004, 45(3), 357-365.
21. Gayed, I.; Vu, T.; Iyer, R.; Johnson, M.; Macapinlac, H.; Swanston, N.; Podoloff, D.; et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med., 2004, 45, 17-21.
22. Shankar, S.; vanSonnenberg, E.; Desai, J.; Dipiro, P. J.; Van Den Abbeele, A.; Demetri, G. D. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology, 2005, 235(3), 892-898.
23. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res., 2003, 9(1), 327-337.
24. Cuenod, C. A.; Fournier, L.; Balvay, D.; Guinebretiere, J. M. Tumor angiogenesis: pathophysiology and implications for contrastenhanced MRI and CT assessment. Abdom. Imag., 2006, 31(2), 188-193.
25. Kan, Z.; Phongkitkarun, S.; Kobayashi, S.; Tang, Y.; Ellis, L. M.; Lee, T. Y.; Charnsangavej, C., Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology, 2005, 237 (1), 151-158.
26. Schlemmer, M.; Sourbron, S. P.; Schinwald, N.; Nikolaou, K.; Becker, C. R.; Reiser, M. F.; Berger, F. Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. Eur. J. Radiol., 2009.
27. Yubao, L. Gastrointestinal Stromal Tumor (GIST): Correlatice Study between 64-Detector Row CT Perfusion and Molecular Pathology. Radiology, 2007, Abstract at the Scientific Assembly and Annual Meeting of the Radiological Society of North America, abstract SSM09-03, 2007.
28. Macari, M.; Spieler, B.; Kim, D.; Graser, A.; Megibow, A. J.; Babb, J.; Chandarana, H. Dual-source dual-energy MDCT of pancreatic adenocarcinoma: initial observations with data generated at 80 kVp and at simulated weighted-average 120 kVp. AJR Am. J. Roentgenol., 194, (1), W27-32.
29. De Giorgi, U.; Aliberti, C.; Benea, G.; Conti, M.; Marangolo, M., Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin. Cancer Res., 2005, 11 (17), 6171-6176.
30. Lassau, N.; Lamuraglia, M.; Vanel, D.; Le Cesne, A.; Chami, L.; Jaziri, S.; Terrier, P.; Roche, A.; Leclere, J.; Bonvalot, S. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann. Oncol., 2005, 16 (7), 1054-1060.
31. Stroobants, S.; Goeminne, J.; Seegers, M.; Dimitrijevic, S.; Dupont, P.; Nuyts, J.; Martens, M.; van den Borne, B.; Cole, P.; Sciot, R.; Dumez, H.; Silberman, S.; Mortelmans, L.; van Oosterom, A. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer, 2003, 39, (14), 2012-2020.
32. Miles, K. A.; Williams, R. E. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging, 2008, 8, 81-86.